CENTRAL RATE CONTRACT NO. -143...NO. 143 EFFECTIVE FROM 03.05.2018 TO 02.05.2020. Sir I Madam,...

ESIC CENTRAL RATE CONTRACT NO. -143

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020)

DRUGS FOR RESPIRATORY SYSTEM DRUGS FOR CARDIO-VASCULAR SYSTEM

DRUGS ACTING ON CENTRAL NERVOUS SYSTEM

STRICTLY FOR OFFICIAL USE

EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN

C.I.G. ROAD, NEW DELHI-110 002

ESIC CENTRAL RATE CONTRACT NO. -143

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020)

DRUGS FOR RESPIRATORY SYSTEM DRUGS FOR CARDIO-VASCULAR SYSTEM

DRUGS ACTING ON CENTRAL NERVOUS SYSTEM

STRICTLY FOR OFFICIAL USE

PUBLISHED BY

DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION

ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI-110 002

Sno. Contents Page No.

1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A).

2. List of Approved Pharmaceutical firms. 1

3. Address with Terms & Conditions of the 1-7

Eligible firms

4. Index 1-2

5. Rate Schedule 1-22

REGISTERED STRICTLY FOR OFFICIAL USE ONLY

HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION

PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI -110 002 TeiFax: 011-23234334, E-mail: [email protected], [email protected]

(An IS0-9001 :2008 Certified)

No.U-25/12/142/2017-Med. V/RC 143 Dated: 3'a May, 2018

From:

To

The Director General, E. S.l. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI- 110 002.

The Director, ESI Scheme -All States Medical Superintendent- ESIC Model Hospitals

Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 143 EFFECTIVE FROM 03.05.2018 TO 02.05.2020.

Sir I Madam,

Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, 03.05.2018. Further, the following instructions are issued to govern operation of the Rate Contract.

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

I

2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof.

3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.

4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

SUPPLIES

5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through email followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone.

6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.

7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.

8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The

ll

Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.

9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.

10. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract.

11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.

12. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.

14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

III

15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials,

bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected.

b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.

c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to

I P I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic

bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of

uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.

g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.

h) Packing should be able to prevent damage or deterioration during transit.

i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents.

j) It should be ensured that lSI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lSI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.

16. Life Period : a) For Drugs having shelf life of Two years or less: Drug supplied

should not be older than one fourth (1/4) of its shelf life from the date of manufacture.

b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply.

17. Pharmacopoeia Specifications: Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act.

IV

18. Testing of Drugs- Quality Contro! a) Approved Rate Contract Holder should submit a Test Report

that particular batch of medicines tested by the Government/ Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply.

b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.

c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs.

d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory.

e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the

v

particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed.

f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier.

The classification of defects into different categories is as per the guidelines issued by the Drug Controller of India & action will be taken by ESIC for each category of defects. described as under:-

A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)-lf any item I Batch of the item declared Not of Standard quality (NSQ) under Category A . • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.

• Forfeiture of Performance Security from the respective DGESIC Rate Contract

• Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT.(Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B

• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.

• Forfeiture of Performance Security from the respective DGESIC Rate Contract.

• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of

VI

any adverse reaction reported in the Hospital during administration of the drugs.

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category 8 within a year • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.


• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract

• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C


• Forfeiture of Performance Security from the respective DGESIC Rate Contract


• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

VII

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year




• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual! individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

19. Delivery Period- ~isk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within

the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the

vnr

pharmaceutical firm, in full at discretion of Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years.

d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate.

20. Payment a. Payment may be made directly to the firm. Payment for the supply will

be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract

b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions.

IX

c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding.

d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever.

e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm.

f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit.

21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts.

22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: -1. The Contractor shall be liable to be debarred for supplying

medicines I drugs etc. to the Corporation for a period not exceeding five years.

ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply

The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:-

PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O. No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if

Drug Date penalty pending levied

1. 2. 3. 4. 5. 6. 7. 8.

X

24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

25. No other document should be entertained for giving any cognizance for placing the supply orders.

26. Acceptance letter issued to the firms by this office cannot be used for placing orders.

Receipt of this letter may please be acknowledged.

Encl.: As above.

Copy to:

Yours faithfully,

~~;f"-/ .

(~Jl;em Logani) Dy. Medical Commissioner (RC)

For: DIRECTOR GENERAL

1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.

2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States)

DY. MEDICAL CO MISSIONER (RC)

~)

XI

Approved Vendor list

SNO. FIRM NAME --1 Abbott Healthcare Private Limited

2 ANGLO FRENCH DRUGS AND INDUSTRIES LIMITED

3 ASTRAZENECA PHARMA INDIA LIMITED

4 Baxter (India) Pvt. Ltd.

s Boehringer lngelheim Indio Pvt. Ltd.

6 CENTAUR PHARMACEUTICALS PVT. LTD.

7 Cipla Ltd

8 Dr Reddys Laboratories Limited

9 Emcure Pharmaceuticals Limited

10 Gennova Biopharmaceuticals Limited

11 GlaxoSmithK/ine Pharmaceuticals Ltd

12 GLENMARK PHARMACEUTICALS LIMITED

13 Hob Pharmaceuticals & Research Ltd

14 INTAS PHARMACEUTICALS LTD

15 JUGGATPHARMA

16 Lupin Ltd.

17 MICRO LABS LTD

18 OVERSEAS HEAL Tfi CARE PVT L TO

19 PSYCHOTROPICS INDIA LIMITED

20 Sandoz Pvt. Ltd.

21 Sanofi India Limited

22 Sanofi Synthelabo {I) Pvt. Ltd.

23 SERDIA PHARMACEUTICALS (INDIA) PVT. LTD.

24 TABLETS (INDIA) LIMITED

25 THEM IS MEDICARE LIMITED

26 TORRENT PHARMACEUTICALS L TO

27 USV Private Limited

Page 1 of 1

Vendor Name

Abbott Healthcare Private Limited

Floor 17, Godrej BI<C, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai-400051 Maharashtra

Tel: 022-2238160527, 7777020398

Term 1

Term 2

Term 3

Term4

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

GST as applicable will be extra except for items where no tax has been approved.

If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.

Supply to be made directly.

Email: [email protected] & [email protected]

Vendor Name

ANGLO FRENCH DRUGS AND INDUSTRIES LIMITED 41 3RD CROSS V BLOCK RAJAJINAGAR, SSI Area, BANGALORE-560010 I<ARNATAKA Tel: 8023154770

Term 1

Term 2

Term 3

Term 4


Vendor Name

ASTRAZENECA PHARMA INDIA LIMITED BLOCK N112TH FLOOR MANYATA EMBASSY BUSINESS PARK RACHENAHALLI OUTER RING ROAD BAN GALORE- 560045KARNATAKA Tel: 080-67748000, 67748857, 9811119532

Email: [email protected]

Vendor Name

Baxter (India) Pvt. Ltd.

2nd Floor, Tower C, Building 8, DLF Cyber City, DLF Phase II Gurgaon-122002 Haryana

Tel: 1244500200,8826103999

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4













Email: [email protected] [email protected]

Page 1 of7

Vendor Name

Boehringer lngelheim India Pvt. Ltd.

1102, 11th Floor, Hallmark Business Plaza, Near Guru Nanak Hospital Road, Bandra East, Mumbai- 400051 Maharashtra

Tel: 22-26456477/78, 9999-385171, 9868-439393

Term 1

Term 2

Term 3

Term 4






Vendor Name

CENTAUR PHARMACEUTICALS PVT. LTD. CENTAUR HOUSE, SHANT! NAGAR, Near Grand Hyatt, VAKOLA SANTACRUZ (East), MUMBAI-400055 MAHARASHTRA

Tel: 22 66499270/274/112, 09833306049


Vendor Name

Cipla Ltd

Cipla Limited, Mumbai Central, Mumbai-400008 Maharastra

Tel: 8879967909


Vendor Name

Dr Reddys Laboratories Limited

7-1-27, Ameerpet-500016, HyderabadTelangana

Tel: 040-49048400

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4






GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.







Page 2of7

Vendor Name

Emcure Pharmaceuticals Limited

Emcure House Plot No. 184, MIDC Bhosari Pune- 411026 Maharashtra

Tel: 2039192761


Vendor Name

Gennova Biopharmaceuticals Limited Survey No. 255/2, Phase-1, Rajiv Gandhi IT Park, MIDC, Hinjwadi, Pune-411057

Tel: 020-39821000, 39821020, 8806120606

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4

Email: [email protected], [email protected]

Vendor Name

GlaxoSmithKiine Pharmaceuticals

ltd GSK House, Dr.Annie Besant Road, Worli Mumbai-400030 Maharashtra

Tel: 022·24959249, 022-24959494, 9920898316

Term 1

Term 2

Term 3

Term 4





Delivery within 6(six) weeks (ofthe actual date of

dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.



Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.




Vendor Name

GLEN MARK PHARMACEUTICALS LIMITED GLEN MARK HOUSE, B D SA WANT MARG, Chakala, ANDHERI (EAST) MUMBAI MAHARASHTRA-400099

Tel: 22-40888925/927, 22-40189988, 09324291478

Term 1

Term 2

Term 3

Term4


Page 3 of 7





Vendor Name

Hab Pharmaceuticals & Research Ltd 308,3rd Floor, T.V Industrial Estate S.K Ahire Marg behind Glaxo Lab, Worli Mumbai Maharashtra-400030

Tel: 022-66261400, 022-66261414, 9930212908


Vendor Name

INTAS PHARMACEUTICALS LTD

2nd Floor, B Wing, Corporate Office, Nr. Sola Bridge, Opp. Zydus Hospital, S.G. Highway, Ahmedabad-380054

Tel: 079-26578862


Vendor Name

JUGGAT PHARMA

782, 15th Cross, I Phase, J.P. Nagar, Bangalore -560078 Bangaluru Karnataka

Tel: 26635026, 26635631, 26635642, 80-26635271


Vendor Name

Lupin Ltd.

3rd Floor, Kalpataru Inspire, Off W.E. Highway, Santacruz (East) Mumbai-400055 Maharashtra

Tel: 022 66402323


Term 1 Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

Term 2 GST as applicable will be extra except for items where no tax has been approved.

Term 3 If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.

Term4 Supply to be made directly.




Term 4 Supply to be made directly.









Page 4 of7

Vendor Name

MICRO LABS LTD

No. 27, RACE COURSE ROAD, BANGALORE KARNATAKA 560001

Tel: 080-22256323, 22370463

Term 1

Term 2

Term 3

Term 4


GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.



Vendor Name

OVERSEAS HEALTH CARE PVT LTD

335 KM MILESTONE, NH N0.1, P.O.BOX-25 PHILLAUR -144410 PUNJAB

Tel: 01826-222886, 01826-222885, 9872019733


Vendor Name

PSYCHOTROPIC$ INDIA LIMITED

PLOT NO. 17 SECTOR- 20 A, FARIDABAD -121001 FARIDABAD HARYANA

Tel: 0129-2296764


Vendor Name

Sandoz Pvt. Ltd.

201, Palika Bhawan, Sector-Xiii, R.K.Puram, New Delhi-110066

Tel: 011-24101308,011-26874021









Term 1 Delivery within 6(six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis





Term 1

Page 5 of7


Vendor Name

Sanofi India Limited

Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai- 110072

Tel: 022-28032000, 28032939


Vendor Name

Sanofi Synthelabo {I) Pvt. Ltd.

Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai- 110072

Tel: 022-28032000, 28032939


Vendor Name

SERDIA PHARMACEUTICALS (INDIA) PVT. LTD. Serdia House, Off. Dr. S. s. Rao Road, Pare I Mumbai Maharashtra 400012

Tel: 022-24196000/24162727


Vendor Name

TABLETS (INDIA) LIMITED

Jhaver Centre, IV Floor, Raja Annamalai Building, 72, Marshalls Road, Egmore, Chennai-600008

Tel: 044-42050000, 28589090, 9380106636


Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4

Page 6 of7








Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.







Vendor Name

THEMIS MEDICARE LIMITED

11/12, Udyog Nagar, SV Road, Gorefaon(West), Mumbai- 400104

Tel: 022-67607080, 267607070

Term 1

Term 2

Term 3

Term 4


GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.


Vendor Name

TORRENT PHARMACEUTICALS LTD

TORRENT HOUSE, OFF ASHRAM ROAD AHMEDABAD GUJARAT 380009

Tel: 079 26585090 I 3060

Term 1

Term 2

Term 3

Term 4

Delivery within 6{six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis



Supply !O be made directly.


Vendor Name

USV Private Limited

Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai- 400088 Maharashtra Tel: 022-25564048


Term 1

Term 2

Term 3

Term 4

Page 7 of7

Delivery within 6{six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.



RC 143 (Index)

Sno. Item No. Item Name and Description Unit Page No.

COUGH SYP- Each Sml to contain: Ambroxol Hydrochloride 30mg

1 1459 Terbutaline Sulphate eqv to Terbutaline 1.25mg, Guaiphenesin 50mg 100m I bot 1

COUGH SYP.- Each 5 ml to contain : Methdilazine 2.5 mg, Amm. Chloride

2 1343 100 mg, sodium citrate 50 mg. 115 ml Bot. 1

Ambroxol Hrdrochloride 30 MG, Terbutaline Sulphate equivalent to

3 2060 terbutaline 2.5 mg Tab 1tab 1

Each 5 ml Contains Ambroxol Hrdrochloride IP 30 mg Terbutaline Sulphate

4 2061 IP equivalent to terbutaline 2.50 mg Guaiphenesin IP 50 Mg MenthoiiP 0.5 100m I bott 1

INHALER- Containing: Moulded plastic device containing a foil strip with30/

60 regularly placed blisters each containing 50 meg of salmeterol xinafoate

5 1520 and 250 meg of Fluticasone propionate 1 dose 2

lndacaterol maleate 143mcg eqv. to 110 meg indacaterol & 63 meg

6 2062 Glycopyrronium Bromide eqv to 50 meg Glycopyrronium. Cap 1 cap 2

FLUTICA50NE+5ALMETROL ROTACAP- Each rotacap to contain: Fluticasone

7 550 250 meg+ Salmetrol 50 meg 1 cap 2

8 1525 TIOTROPIUM BROMIDE 18mcg ROTACAP 1 cap 3

9 2015 BECLOMETHASONE DIPROPIONATE IP 200MCG (HFA TECHNOLOGY) 200MDI 3

BUDESONIDE RESP.- Each 2m I to contain :Budesonide 1mg Steriod

10 1524 Nebulizing Fluid 2m I. amp. 3

11 2064 Budesonide 0.5mg+ l.evosalbutamol1.25m!l_ Resp. 2m I amp 3 METOPROLOL ER TAB- Each ER tab to contain: Metoprolol Succinate

12 525a -· 47.5mg equivalent to Metoprolol Tartrate SOmg. 1 tab 4

METOPROLOL SUCCINATE SR TAB- Each SR tab to contain: Metoprolol

13 1845 Succinate 23.75mg equivalent to Metoprolol Tartrate 25mg 1 tab 4

Each Prolonged Release Film coated Tablet to contain: 5(-)Metoprolol

14 2067 succinate 47.50 mg Eqv. to 5(-) Metoprolol Tartrate 50 mg 1 tab 5 15 2068 Each Tablet to contain : S-Metoprolol 25 mg 1 tab 5

16 422 AMIODARONE TAB- Each tab to contain: Amiodarone HCL 100mg. 1 tab 5

17 597 AMIODARONE INJ- Each ml to contain: Amiodarone SOmg. 3ml inj 5

18 1063 TRIMETAZIDINE TAB- Each tab to contain :Trimetazidine Hcl 20 mg. 1 tab 6

19 1851 MOXON I DINE TAB- Each tab to contain: Moxonidine 0.2mg 1 tab 6

20 2069 Ticagrelor 90mg Tab 1 tab 6

21 2070 lvabradine hcl equivalent to lvabradine7.5mg Tab 1 tab 7

22 2071 Sacubitril24mg and 26mg valsartan Tab 1tab 7

23 2072 5acubitril 49mg and 51mg valsartan Tab 1 tab 7

24 56b ENALAPRIL MALEATE 5mg TAB 1tab 7

25 1068c RAMIPRIL 5mg TAB/CAP 1 tab/cap 8

26 470c PERINDOPRIL 8mg TAB 1 tab 8

27 1372 PERINDOPRIL 4mg+ INDAPAMIDE 1.25mg TAB 1 tab 8

28 1373 ATENOLOL SOmg + AMLODEPINE Smg TAB 1tab 9

29 1420 TELMISARTAN TAB- Each tab: Telmisartan 40mg 1 tab 9

30 1668 OLMESARTAN 20 mg TAB/CAP 1 tab/cap 10

31 336a CARVEDILOL TAB- Each Tab: Carvedilol 3.125mg. 1tab 10

Page 1 of 2

RC 143 {Index) .

Sno. Item No. Item Name and Description Unit Page No.

32 1349 METOLAZONE TAB- Each Tab: Metolazone 5mg. ltab 10

33 574 METOPROLOL INJ- Each mi.: Metoprolol1mg. 5ml 11

34 1370 TORSEMIDE TAB· Each tab: Torsemide 10mg ltab 11

Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine

HCL IP 20mg, (Each ml to contains approx lmEq Magnesium lon, 2mEq

35 2075 Patassium lon, 3mEq Citrate lon and 4mg of Pyridoxine HCL) in Each 5 ml 200m I batt 11

36 63 ISOXSUPRINE INJ- Each ml to contain: lsoxsuprine 5mg. 2m I amp 11

HAEMOSTATIC TAB- Each tab. to contain: Micronized purified Flavonoid

37 322 fraction of Rutaceae 500mg ltab 12

HAEMOSTATIC- Each 5ml to contain: Haemostatic Matrix with Prefilled

38 1670 Gelatin Granules in Syringes 5ml 12

39 68a ETHAMSYLATE TAB- Each Tab to contain Ethamsylate 250 mg. 1 Tab 12

FONDAPARINUX SODIUM JNJ- Each PFS to contain: Fondaparinux Sodium

40 1536 2.5mg 0.5ml PFS 12

Micronised ·purified flavonoid fraction 1000mg composed of diosmin

41 2076 900mg {90%) and flavonoids expressed as hesperidin 100mg (10%) Ta~-- 1 tab 13

Hemostat containing: Hemostatic matrix with thrombin in prifilled syringe

42 2077 10m I 1 PFS 13

43 429 CLOPJDOGREL TAB- Each tab to contain: Clopidogrel 7Smg. 1 tab 13 44 1752 TENECTEPLASE 40MG INJ 1 vial 14

45 2080 Dabigatran 110mg Cap 1 cap 14 ---ANTICOAGULANTS-Each Kit to contain:Two componant fibrin sealant with

46 2081 synthetic Aprotinin (4ml) 4ml 14

47 474b OLANZAPINE Smg TAB 1 tab 15

48 96 IMIPRAMINE TAB- Each tab to contain: Imipramine 25mg. 1 tab 15

49 556a ESCITALOPRAM 10mg TAB 1 tab 16

50 556b ESCITALOPRAM 20mg TAB 1 tab 16

51 1681 CITICOLINE TAB- Each tab to contain: Citicoline 500 mg ltab 17

52 540 SULBUTIAMINE 200mg TAB 1 tab 17

53 98 PHENYTOIN SODIUM lOOmg TAB 1 tab 17

SODIUM VALPROATE + VALPROIC ACID CR TAB- Each CR tab to contain:

54 433b (Sodium Valproate + Valproic Acid) eqv. to Sodium Valproate 500mg. 1 tab 18

55 324a CLOBAZAM TAB- Each tab to contain: Clobazam 5 mg ltab 18

56 324b CLOBAZAM TAB- Each tab to contain: Clobazam I.P.lO mg 1 tab 18

57 1392 OXCARBAZEPINE 150mg TAB 1 tab 19

58 1879 LEVETIRACETAM 500mg TAB 1 tab 19

59 1880 LEVETIRACETAM 250mg TAB 1 tab 20

60 1882 LAMOTRIGINE 25mg DISP. TAB 1 tab 20

61 1883 LAMOTRIGINE 100mg TAB 1 tab 21

62 1120 LITHIUM CR 450mg TAB 1 tab 21

63 1682 DIVALPROEX SOD. 250mg SR/ER/CR Tab ltab 21

64 1683 DIVALPROEX SOD. SOOmg SR/ER/CR Tab 1 tab 21

65 1131 SODIUM VALPROATE 200mg TAB 1 tab 22

Page 2 of 2

Employees' State Insurance Corporation

Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143

Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020

litem No I Drug Description

Firm Name Firm Rate/ unit Firm Packing Preference

1459 COUGH SYP - Each 5ml to contain: Ambroxol Hydrochloride 30mg Terbutaline Sulphate eqv to Terbutaline 1.25mg, Guaiphenesin 50mg Menthol 0.5mg


27.1/lOOml bot 100ml bott FIRST

Rupees twenty seven paisa ten only

I Packing

Description of stores accepted

lOOml bot

AMBROLITE S+ SYRUP

SAME AS IN ITEM

1343

/

COUGH SYP. - Each 5 ml to contain : Methdilazine 2.5 mg, 1115 ml Bot. Amm. Chloride 100 mg, sodium citrate 50 mg.

GlaxoSmithKiine 41.61/115 ml 115ml Bott FIRST Dilosyn Expectorant Pharmaceuticals Ltd Bot.

SAME AS IN ITEM

Rul)ees forty one paisa sixty one only

2060 Each Uncoated tablet contains Arnbroxol Hrdrochloride 30 MG 1 tab Terbutaline Sulphate equivaler\t to terbutaline 2.5 mg

TABLETS (INDIA) 3.41/1 tab 10 tab FIRST LIMITED

Rupees three paisa forty one only

2061 Each 5 ml Contains Arnbroxol Hrdrochloride IP 30 mg Terbutaline Sulphate IP equivalent to terbutallne 2.50 rng Guaiphenesin IP 50 MgMenthoiiP 0.5 rng


38.38/100ml bott

lOOm! bott FIRST

Rupees thirty eight paisa thirty eight only

Page 1 of 22

AMBROLITE ST

SAME AS IN ITEM

100m I bott

AMBROLITE 25 SYRUP

SAME AS IN ITEM



Valid from Thursday May 3'd 2018 to Saturday May znd 2020

[ttem No I Drug Description


1520 INHALER - Containing: Moulded plastic device containing a foil strip with30/ 60 regularly placed blisters each containing 50 meg of salmeterol xinafoate and 250 meg of Fluticasone propionate

Glaxo5mlthKhne 5.72/1 dose 60 Bhster FIRST

Pharmaceuticals Ltd

Rupees five paisa seventy two only

2062 Each cap contains : 143 meg indacaterol maleate eqv. to 110 meg indacaterol & 63 meg Glycopyrronium Sromide eqv to 50 meg Glycopyrronium.

Sandoz Pvt. Ltd. S3.2527/1 cap 30capand 1 inhaler

FIRST

Rupees fifty three paisa two five two seven only

I Packing


1 dose

Seret1de Accuhaler

50/250 MCG Mfg.: Glaxo Wellcome Production,

France SAME AS IN ITEM

1 cap

Sequadra Mfg.: Novartls

Pharma Stein AG,

Switzerland SAME AS IN ITEM

550 FLUTICASONE+SALMETROL ROTACAP - Each rotacap to 1 cap contain: Fluticasone 250 rnc · + Salrnetrol 50 meg

Cipla Ltd

Lupin Ltd.

GLEN MARK

PHARMACEUTICALS

LIMITED

1.5967/1 cap 30 cap FIRST SEROFLO 250 ROTACAPS SAME AS IN ITEM

Rupees one paisa five nine six seven only

1.656/1 cap 30cap SECOND Esiflo 250 Transcaps SAME AS IN ITEM

Rupees one paisa six five six only

4.23/1 cap ~0 cap THIRD AIRTEC SF 250- DPI

SAME AS IN ITEM

Rupees four paisa twenty three only

Page 2 of22




lttem No

Firm Name

1525

Lupin Ltd.

Cipla ltd

2015

Cipla Ltd

1524

Cipla Ltd

I Drug Description

Firm Rate/ unit Firm Packing Preference

TIOTROPIUM BROMIDE ROTACAP - Each rotacap to contain : Tiotropium Bromide I.P./BP eqv. to Tiotropium Bromide

Monohydrate :L8mcg.

:1.2563/1 cap 30Cap FIRST

Rupees one paisa two five six three only

I Packing


1 cap

Tlate Transcaps SAME AS IN ITEM

:1.4313/1 cap 15 cap SECOND TIOVA ROTACAPS SAME AS IN ITEM

Rupees one paisa four three one three only

BECLOMETHASONE DIPROPIONATE IP 200MCG (HFA TECHNOLOGY) INHALER - Each metered dose to contain: Beclomethasone Dipropionate IP 200mcg (HFA Technology)

68.74/200MDI 200MDI FIRST

Rupees sixty eight paisa seventy four only

200MDI

BECLATE CFC FREE INHALER200 SAME AS IN ITEM

BUDESONIDE RESP. - Each 2ml to contain :Budesonide 1mg 2ml. amp. Steriod Nebulizing Fluid

6.48/2rnl. amp. 2 rnl FIRST BUDECORT lMG RESPULE SAME AS IN ITEM

Rupees six paisa forty eight only

2064 Each amp to contain: Budesonide O.Smg+ Levosalbutamol 2m I amp 1.25mg

Cipla Ltd 19.5/2ml amp 2Ml FIRST

Rupees.nineteen paisa fifty only

Page 3 of 22

BUDESAL O.SMG RESPULE SAME AS IN ITEM

Employees' S'tate Insurance Corporation



litem No I Drug Description I Packing

Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted

525a METOPROLOL ER TAB - Each ER tab to contain: Metoprolol lltab Succinate 47.5mg equivalent to Metoprolol Tartrate SOmg.

Cipla Ltd

I NT AS

PHARMACEUTICALS

LTD

MICRO LABS LTD

0.7133/1 tab 15 tab FIRST METOLAR XR 50 SAME AS IN ITEM

Rupees Zero paisa seven one three three only

0.95/1 tab 30tab SECOND EM BETA XR-50

Rupees zero paisa ninety five only

0.96/1 tab 15 tab THIRD

Rupees zero paisa ninety six only

SAME AS IN ITEM

METAPRO XL 50 SAME AS IN ITEM

1845 METOPROLOL SUCCINATE SR TAB • Each SR tab to contain: 1 tab Metoprolol Succinate 23.75mg equivalent to Metoprolol

Tartrate 25mg

Cipla ltd 0.558/1 tab 1Stab FIRST

Rupees zero paisa five five eight only

METOLAR XR 25 SAME AS IN ITEM

I NT AS 0.66/1 tab 30tab SECOND EM BETA XR-25

PHARMACEUTICALS

LTD

MICRO LABS L TO

Rupees zero paisa sixty six only


Rupees zero paisa seventy four only

Page 4 of22

SAME AS IN ITEM

METAPRO XL 25 SAME AS IN ITEM

I



Valid from Thursday May 3'd 2018 to Saturday May znd 2020

[ttem No [ Drug Description [Packing

Firm Name Firm Rate/ unit Firm Packing Preference Description of stores

2067 Each Prolonged Release Film coated Tablet to contain : S(-)Metoprolol succinate 47.50 Tartrate 50 mg

Em cure Pharmaceuticals Limited

6.97/1 tab

mg Eqv. to S(-) Metoprolol

10tab FIRST

Rupees six paisa ninety seven only

I 2o6s I Each Tablet to contain : S-Metoprolol 25 mg


5.97/1 tab 10 tab FIRST

Rupees five paisa ninety seven only

accepted

ltab

METPURE-XLSO

SAME AS IN ITEM

11 tab

METPURE-XL 25

SAME AS IN ITEM

422 AMIODARONE TAB - Each tab to contain: Amiodarone HCL 1 tab 100m g.

MICRO LABS LTD 1.68/1 tab 10 tab FIRST AMIODAR 100 SAME AS IN ITEM

Cipla ltd

Cipla Ltd

Rupees one paisa sixty eight only

2.2/1 tab 10tab SECOND TACHYRA 100 SAME AS IN ITEM

Rupees two paisa twenty only

I AMIODARONE INJ- Each ml to contain: Amiodarone 50mg. 13ml inj

35/3ml.inj 3 ml FIRST TACHYRA SAME AS IN ITEM

Rupees thirty five only

Sanofi Synthelabo (I) 50.08/3ml inj Pvt. Ltd.

3ml amp. SECOND Cordarone lnj

SAME AS IN ITEM

Rupees fifty paisa eight only

Page 5 of22




I Item No I Drug Description I Packing


1063 TRIMETAZIDINE TAB - Each tab to contain :Trimetazidine Hcl 11 tab 20mg.

THEM IS MEDICARE 0.528/1 tab 10 tab FIRST THEMIDON LIMITED

SAME AS IN ITEM

Rupees zero paisa five two eight only

Cipla Ltd 0.57/1 tab 10tab SECOND TRIVEDON 20 SAME AS IN ITEM

Rupees zero paisa fifty seven only

SERDIA 6.429/1 tab l.O tab THIRD PHARMACEUTICALS (INDIA) PVf LTD

Rupees six paisa four two nine only

I 1851 I MOXONIDINE TAB- Each tab to contain: Moxonidine 0.2mg

MICRO LABS LTD 2.33/1 tab 10 tab FIRST

Rupees two paisa thirty three only

I 2069 I Each Tab to contains:Ticagrelor 90mg

ASTRAZENECA 20.05/1 tab 14 tab FIRST PHARMA INDIA LIMITED

Rupees twenty paisa five only

Page 6 of22

FLAVEDON 20

SAME AS IN ITEM

I 1 tab

MOXILONG 0.2 SAME AS IN ITEM

I 1 tab

BRILl NTA 90MG Mfg.: AstraZeneca Operations, AB Sweden SAME AS IN ITEM

I




lttem No I Drug Description I Packing


2070 Each Film Coated tab contain: lvabradine hcl equivalent to 1 tab lvabradine7.5mg

SERDIA 16.99/1 tab 14 tab FIRST CORALAN 7.5mg Mfg.: PHARMACEUTICALS

(INDIA} PVT LTD

Rupees sixteen paisa ninety nine only

2071 Each film coated tablet contains: 24mg sacubitril and 26mg valsartan as sodium salt complex

Sandoz Pvt. Ltd. 44.8858/1 tab 14 tab FIRST

Rupees ·forty four paisa eight eight five eight only

Les Laboratories Servier Industries, France SAME AS IN ITEM

1 tab

Vymada 50mg Mfg.: Novartis Farma SpA., Italy SAME AS IN ITEM

!2012 Each film coated tablet contains: 49mg sacubitril and 51mg 1 tab L valsartan as sodium salt complex

Sandoz Pvt. Ltd. 48.7336/1 tab 14 tab FIRST Vymada lOOmg Mfg.: Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM

Rupees. forty eight paisa seven three three six only

56b ENALAPRIL MALEATE TAB - Each tab to contain: Enalapril 1 tab Maleate Smg.

I NT AS PHARMACEUTICALS

LTD

0.46/1 tab 15 tab FIRST ENAPRIL5

SAME AS IN ITEM

Rupees zero paisa forty six only

Dr Reddys 0.7887/1 tab 15 tab SECOND Enam SMG Laboratories Limited

SAME AS IN ITEM

Rupees zero paisa seven eight eight seven only

Page 7 of22






/t068c / RAMIPRIL TAB/CAP- Each tab/cap to contain: Ramipril Smg. It tab/cap

Cipla Ltd 1.45/1 tab/cap 10 tab FIRST

Rupees one pais:~ forty five only

RAMIPRES-5 SAME AS IN ITEM

Sanofi India Limited 4.49/1 tab/cap 10 tab SECOND Cardace 5 mg SAME AS IN ITEM

Rupees four paisa forty nine only

MICRO LABS LTD 5.02/1 tab/cap 15 tab THIRD HOP ACE 5 SAME AS IN ITEM

Rupees five paisa two only

PERINDOPRIL TAB- Ea·c·h tab to conta.in: Perindopril Erbumi.ne 11 tab

Bmg. _ _ .. ---~~--~~.---------470c

SERDIA PHARMACEUTICALS (INDIA) PVT LTD

11.429/1 tab 10 tab FIRST COVERSYL8mg

SAME AS IN ITEM

Rupees eleven paisa four two nine only

1372 PERINDOPRIL+ INDAPAMIDE TAB - Each tab to contain: 1 tab Perindopril Erbumine 4rng, lndapamide 1.25mg

GLEN MARK 7. 7/1 tab 10 tab PHARMACEUTICALS LIMITED

FIRST

Rupees seven paisa seventy only

PERIGARD DF

SAME AS IN ITEM

SERDIA PHARMACEUTICALS (INDIA) PVT LTD

11.429/1 tab 10tab SECOND COVERSYL PLUS

SAME AS IN ITEM

Rupees eleven paisa four two nine only

Page 8 of 22






1373 ATENOLOL + AMLODEPINE TAB- Each tab to contain: Atenolol 1 tab 50mg, Am lode pine Smg

Hab Pharmaceuticals 0.28/1 tab 10 x 10 tab FIRST CARDINOL PLUS & Research Ltd

SAME AS IN ITEM

Rupees zero paisa twenty eight only

PSYCHOTROPICS INDIA LIMITED

0.29/1 tab 14tab SECOND ETOPRESS AT 50

I NT AS PHARMACEUTICALS LTD

Rupees zero paisa twenty nine only

0.36/1 tab 15 tab TI-IIRD

Rupees zero paisa thirty six only

11420 I TELMISARTAN TAB- Each tab to contain: Telmisartan 4bmg

PSYCHOTROPICS 0.69/1 tab 10 tab FIRST INDIA LIMITED

Rupees zero paisa sixty nine only

SAME AS IN ITEM

AMTAS-AT

SAME AS IN ITEM

11 tab TAB TELPIL40

SAME AS IN ITEM

USVPRIVATE LIMITED

0.9S3/1 tab 10tab SECOND Tazloc 40mg


Rupees zero paisa nine five three only


Rupees one paisa twenty seven only

Page 9 of22

SAME AS IN ITEM

TEMSAN-40

SAME AS IN ITEM




[item No I Drug Description I Packing


1668 OLMESARTAN TAB/CAP- Each tab/cap to contain: Olmesartan 1 tab/cap 20m g.

PSYCHOTROPIC$ 0.87/1 tab/cap 10 tab FIRST TAB OLIPIL 20 INDIA LIMITED

SAME AS IN ITEM

Rupees zero paisa eighty seven only

Cipla Ltd 1.25/1 tab/cap 10 tab SECOND OLMECIP 20 SAME AS IN ITEM

USVPRIVATE LIMITED

Rupees one paisa twenty fiv.e only

1.59/1 tab/cap 10 tab THIRD

Rupees one paisa fifty nine only

I 336a I CARVEDILOL TAB- Each Tab to contain: Carvedilol 3.125mg. I NT AS PHARMACEUTICALS LTD


Rupees zero paisa thirty three only

11349 I METOLAZONE TAB- Each lab tocontain Metolazone Smg.

CENTAUR 7.5/1 tab 10 tab FIRST PHARMACEUTICALS PVT. LTD

Rupees seven paisa fifty ohly

Page 10 of22

Olmetrack 20mg

SAME AS IN ITEM

11 tab

CMCA 3.125

SAME AS IN ITEM

11 tab

METOZ5

SAME AS IN ITEM






ls74 I METOPROLOL INJ - Each mi. to contain: Metoprolollmg.

Cipla Ltd 10.5/5ml 5 ml FIRST

Rupees ten paisa fifty only

11370 I TORSEMIDE TAB- Each tab to contain: Torsemide 10mg


Rupees zero paisa ninety seven only

accepted

lsml

METOLAR SAME AS IN ITEM

11 tab

TORSINEX10 SAME AS IN ITEM

Cipla Ltd 1.9733/1 tab 15tab SECOND DVTOR 10

Rupees one paisa nine seven three three only

2075 Each Sml contains :Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine HCL IP 20mg, (Each ml to contains approx lmEq Magnesium lon, 2mEq Patassium lon, 3mEq Citrate lon and 4mg of Pyridoxine HCL)

OVERSEAS HEALTH

CAREPVTLTD

80/200ml bott 200 ml bott. FIRST

Rupees eighty only

I 63 jiSOXSUPRINE INJ - Each ml to contain: lsoxsuprine Smg.

JUGGAT PHARMA 9/2ml amp 5X2ml FIRST

Rupees nine only

Page 11 of 22

SAME AS IN ITEM

200m I bott

ALKAMAXMB6

SAME AS IN ITEM

j2mlamp

Tidilan Injection SAME AS IN ITEM




lttemNo I Drug Description I Packing


322 HAEMOSTATIC TAB- Each tab. to contain: Micronized purified 1 tab Flavonoid fraction of Rutaceae 500mg

SERDIA 8.143/1 tab 10 tab FIRST DAFLON PHARMACEUTICALS {INDIA) PVT LTD

Rupees eight paisa one four three only

SAME AS IN ITEM

1670 HAEMOSTATIC- Each Sml to contain: Haemostatic Matrix with Sml Prefilled Gelatin Granules in Syringes

Baxter (India) Pvt. Ltd 12500/5ml 5ml FIRST

Rupees twelve thousand five hundred only

I 68a I ETHAMSYLATE TAB- Each Tab to contain Ethamsylate 250 mg.

JUGGAT PHARMA 4.6941/1 Tab 10 tab FIRST

Rupees four paisa six nine four one only

Floseal Mfg. Baxter Healthcare Corporation, USA SAME AS IN ITEM

11 Tab

Botrostat Tablet SAME AS IN ITEM

1536 FONDAPARINUX SODIUM INJ - Each PFS to contain: O.Sml PFS Fondaparinux Sodium 2.5mg

Dr Reddys 330/0.Srnl PFS 1PF5 FIRST Fonda Red 2.5 lnj Laboratories Limited

SAME AS IN ITEM

Rupees three hundred thirty only

Page 12 of 22



Valid from Thursday May 3rrl 2018 to Saturday May 2"d 2020

I Item No I Drug Description


2076 Each film coated tablet contains micronised - purified flavonoid fraction 1000mg composed of diosmin 900mg (90%) and flavonoids expressed as hesperidin 100mg (10%)

SERDIA

PHARMACEUTICALS

(INDIA) PVT LTD

13.214/1 tab 10tab FIRST

Rupees thirteen paisa two hundred fourteen only

2077 Hemostat containing: Hemostatic matrix with thrombin in prifilled syringe 10m I

Baxter (India) Pvt. Ltd 21995/1 PFS 1 PFS FIRST

I Packing


1 tab

DAFLON lOOOmg

SAME AS IN ITEM

1 PFS

Floseal Mfg. Baxter

Healthcare Corporation,

USA SAME AS IN ITEM

Rupees twenty one thousand nine hundred ninety five only

I 429 I CLOPIDOGREL TAB- Each tab to contain: Clopidogrel75mg. I 1 tab Hab Pharmaceuticals 0.9/1 tab 10 tab FIRST LAVIX-75 & Research Ltd

SAME AS IN ITEM

Rupees zero paisa ninety only

Clpla Ltd 0.9933/1 tab 15 tab SECOND CLOPIVAS 75 SAME AS IN ITEM

I NT AS

PHARMACEUTICALS

LTD

Rupees zero paisa nine nine three three only


Rupees one paisa six only

Page 13 of22

CLAVIX-75

SAME AS IN ITEM

J



Valid from Thursday May 3rd 2018 to Saturday May 2"d 2020

/Item No I Drug Description I Packing


1752 TENECTEPLASE 40MG INJ - Each vial to contain: Tenecteplase 1 vial 40mg

Gennova Biopharmaceuticals Limited

23237/1 vial 1 Vial FIRST ELAXIM 40 MG INJECTION

SAME AS IN ITEM

Rupees twenty three thousand two hundred thirty seven only

Boehringer lngelheim 23428.12/1 vial 1 Vial India Pvt. LTd.

SECOND METALYSE 40 MG Mfg.: Boehringer lngelheim Pharma GmbH & Co, Germany SAME AS IN ITEM

Rupees twenty three thousand four hundred twenty eight paisa twelve only

2080 Dabigatran Cap: Each Cap to contains: Dabigatran Etexitate 1 cap 110 mg

Boehringer lngelheim 50/1 cap India Pvt. LTd.

10 cap

Rupees fifty only

FIRST CAP PRADAXA 110 MG Mfg.; Boehringer lngelheim Pharma GmbH

& Co, Germany SAME AS IN ITEM

2081 ANTICOAGULANTS-Each Kit to contain:Two componant fibrin 4ml sealant with synthetic Aprotinin (4ml)

Baxter (India) Pvt. Ltd 12900/4ml 4ml FIRST Tisseel Lyo Mfg. Baxter AG, Austria. SAME AS IN ITEM

Rupees twelve thousand nine hundred only

Page 14 of22






I 474b I OLANZAPINE TAB- Each tab to contain: Olanzapine Smg 11 tab

Hab Pharmaceuticals 0.32/1 tab 10 x 10 tab FIRST OLANZAP-5 & Research Ltd

SAME AS IN ITEM

Rupees zero paisa thirty two only


0.33/1 tab lOtab SECOND TAB OZACE 5


Rupees zero paisa thirty three only

0.39/1 tab 10tab THIRD

Rupees zero paisa thirty nine only

!IMIPRAMINE TAB- Each tab to contain: Imipramine 25mg.



Rupees zero paisa thirty nine only

SAME AS IN ITEM

OLIZA 5

SAME AS IN ITEM

11 tab

OEPSOL25

SAME AS IN ITEM


0.4/1 tab 10tab SECOND DEPSONIL 25MG


0.51/1 tab

Rupees zero paisa forty only

10 tab THIRD

Rupees zero paisa fifty one only

Page 15 of22

SAME AS IN ITEM

ELOEP 25

SAME AS IN ITEM





Firm Name Firm Rate/ unit Firm Packing Preference Description af stores accepted

I 556a I ESCITALOPRAM TAB- Each tab to contain: Escitalopram 10 mg. 11 tab

Hab Pharmaceuticals 0.45/1 tab 10 x 10 tab FIRST ES- LEXXA & Research Ltd



0.69/1 tab

0.81/1 tab

SAME AS IN ITEM

Rupees zero paisa forty five only

10tab SECOND REXIPRA-10

SAME AS IN ITEM

Rupees zero paisa sixty nine only

10tab THIRD ECINIL 10

SAME AS IN ITEM

Rupees zero paisa eighty one only

lss6b I ESCITALOPRAM TAB- Each tab to contain: Escitalopram 20 mg. 11 tab .



Lupin Ltd.

1.29/1 tab 10 tab FIRST REXIPRA-20

SAME AS IN ITEM

Rupees one paisa twenty nine only

1.38/1 tab 10tab SECOND ECINIL 20

Rupees one paisa thirty eight only

2.2137/1 tab lOtab THIRD

Rupees two paisa two one three seven only

Page 16 of22

SAME AS IN ITEM

Stalopam 20 SAME AS IN ITEM



Valid from Thursday May 3m 2018 to Saturday May 2"d 2020



J1681 I CITICOUNE TAB- Each tab to contain: Citicoline 500 mg 11 tab

USV PRIVATE 13.068/1 tab 10 tab FIRST Citinerve 500mg LIMITED


SAME AS IN ITEM

Rupees thirteen paisa leto six eight only

20.16/1 tab 10tab SECOND STROLIN

SAME AS IN ITEM

Rupees twenty paisa sixteen only

SULBUTIAMINE TAB - Each tab to contain: Sulbutiamine 1 tab = L_ ________ ~20~0~m~g·--~~~~----~--~------~~~--~~~~~--

540

SERDIA 11.071/1 tab 10 tab FIRST AltCALION PHARMACEUTICALS (INDIA) PVT LTD

SAME AS IN ITEM

Rupees eleven paisa zero seven one only

98 PHENYTOIN SODIUM TAB - Each tab to contain: Phenytoin 1 tab sodium lOOmg.

ANGLO FRENCH 0.41/1 tab 10 tab FIRST PHENYTOS DRUGS AND SAME AS IN ITEM INDUSTRIES LIMITED

USV PRIVATE LIMITED


Rupees zero paisa forty one only

0.522/1 tab Bottle of 90 tab SECOND CToin 100mg

Rupees zero paisa five two two only

0.88/1 tab Bottle of 120 tab

THIRD

Rupees zero paisa eighty eight only

Page 17 of 22

SAME AS IN ITEM

EPfOIN lOOMG SAME AS IN ITEM



Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020



433b SODIUM VALPROATE + VALPROIC ACID CR TAB- Each CR tab to contain: (Sodium Valproate + Valproic Acid) eqv. to Sodium Valproate SOOmg.



Rupees one paisa ninety one only

accepted

1 tab

VALATE CHRONO 500

SAME AS IN ITEM

MICRO LABS LTD 2.94/1 tab 10tab SECOND VALPRID CR 500 SAME AS IN ITEM

Rupees two paisa ninety four only

Sanofi Synthelabo (1) 5.03/1 tab 10tab THIRD Pvt. Ltd.

Rupees five paisa three only

I 324a I CLOBAZAM TAB- Each tab to contain: Clobazam 5 mg


Rupees one paisa sixty three only

Valparin Chrono 500

SAME AS IN ITEM

11 tab

YOGAZAM5 SAME AS IN ITEM

Sanofi India Limited 3.73/1 tab 15tab SECOND Fresium 5 mg SAME AS IN ITEM

Rupees three paisa seventy three only

I 324b I CLOBAZAM TAB- Each tab to contain: Clobazam I.P.10 mg


Rupees two paisa forty two only

11 tab

YOGAZAM 10 SAME AS IN ITEM

Sanofi India Limited 6.56/1 tab lS tab SECOND Fresium 10 mg SAME AS IN ITEM

Rupees six paisa fifty six only

Page 18 of22



Valid from Thursday May 3rd 2018 to Saturday May 2nd 2020

[ttem No I Drug Description I Packing


1392 OXCARBAZEPINE TAB - Each tab to contain: Oxcarbazepine 1 tab 150mg

I NT AS

PHARMACEUTICALS

LTD

MICRO LABS LTD

TORRENT

PHARMACEUTICALS

LTD

1.49/1 tab

2.08/1 tab

2.27/1 tab

10tab FIRST ZENOXA-1SO

SAME AS IN ITEM

Rupees one paisa forty nine only

10tab SECOND CARBOX 150 SAME AS IN ITEM

Rupees two paisa eight only

15 tab THIRD OLEPTAL 150 DT

SAME AS IN ITEM

Rupees two paisa twenty seven only

11879 I

LEVETIRACETAM TAB - Each tab to contain: 500mg

l.evetiracetam 1 tab

Cipla Ltd

I NT AS

PHARMACEUTICALS

LTD

Lupin Ltd.


Rupees two paisa six nine three three only

LEVEPSY 500 SAME AS IN ITEM

3.27/1 tab 15tab SECOND LEVERA 500

Rupees three paisa twenty seven only

3.4418/1 tab 10Tab THIRD

Rupees three paisa four four one eight only

Page 19 of22

SAME AS IN ITEM

Epilive 500 SAME AS IN ITEM




[Item No [ Drug Description [Packing


1880 LEVETIRACETAM TAB - Each tab to contain: 250mg

Levetiracetam 11 tab


Cipla ltd

lupin ltd.

1.69/1 tab 10 tab FIRST LEVERA 2SO MG

SAME AS IN ITEM

Rupees one paisa sixty nine only

1.7/1 tab 15 tab SECOND LEVEPSY 2SO SAME AS IN ITEM

Rupees one paisa seven thousand only

1.9722/1 tab 10tab THIRD

Rupees one paisa nine seven two two only

Epilive 250 SAME AS IN ITEM

1882 LAMOTRIGINE DISP. TAB - Each disp tab to contain: 1 tab Lamotrigine 25rllg

Cipla ltd 0.78/1 tab 10 tab FIRST LAMETEC 25 DT SAME AS IN ITEM

Rupees zero paisa seventy eight only

GlaxoSmithKiine 3.69/1 tab Pharmaceuticals ltd

14tab SECOND lamictal Dispersible Tablet 25 MG SAME AS IN ITEM

Rupees three paisa sixty nine only

Page 20 of22

I




!Item No I Drug Description I Packing


11883 I LAMOTRIGINE TAB- Each tab to contain: Lamotrigine 100mg



Rupees one paisa forty three only

accepted

!1 tab

LAMITOR 100 DT

SAME AS IN ITEM

GlaxoSmithKiine 10.56/1 tab Pharmaceuticals Ltd

14tab SECOND Lamictal Dispersible Tablet 100 MG SAME AS IN ITEM

Rupees ten paisa fifty six only

11120 I LITHIUM CR TAB- Each CR tab to contain : Lithium Carbonate 450mg.

I NT AS

PtiARMACEUTICALS

LTD

1. 79/1 tab 10 tab FIRST

Rupees one paisa seventy nine only .

1 tab

iNTAliTH CR 450

SAME AS IN ITEM

r 1682 1 DIVALPROEX 500, TAB Divalproex Sod. 250mg

Each SR/ER/CR tab to contain: 1 tab


2.2/1 tab· 10tab FIRST

Rupees two )!laisa twenty only

TREND XR250 (Prolonged Release)

SAME AS IN ITEM

r 1683 DIVALPROEX SOD. TAB Divalproex Sod. SOOmg

Each SR/ER/CR tab to contain: 1 tab

TORRENT

PHARMACEUTICALS LTD


Rupees three paisa forty only

Page 21 of22

TRENDXRSOO (Prolonged Release)

SAME AS IN ITEM

I




lttem No I Drug Description I PQcking

FirmNQme Firm RCltej unit Firm Packing Preference Description of stores accepted

1

11.31 !SODIUM VALPROATE TAB Valproate 200mg.

Each Tab to contain: Sodium 1 tab

PSYCHOTROPICS 0.81/1 tab 10tab FIRST VALATE 200 INDIA LIMITED

SAME AS IN ITEM

Rupees zero paisa eighty one only

Hab Pharmaceuticals 1.56/1 tab 10tab SECOND EPIVALPRATE -200 & Research Ltd

SAME AS IN ITEM

Rupees one paisa fifty six only

Sanofi Synthelabo (I) 2.25/1 tab 10tab THIRD Valparin Alkalets 200 Pvt. Ltd.

SAME AS IN ITEM

Rupees two paisa twenty five only

Page 22 of 22

CENTRAL RATE CONTRACT NO. -143...NO. 143 EFFECTIVE FROM 03.05.2018 TO 02.05.2020. Sir I Madam,...

Documents

Transcript of CENTRAL RATE CONTRACT NO. -143...NO. 143 EFFECTIVE FROM 03.05.2018 TO 02.05.2020. Sir I Madam,...